Outcome of COVID-19 infection in patients on antihypertensives:A cross-sectional study  

作　　者：Sakthivadivel Varatharajan Gopal K Bohra Pradeep K Bhatia Satyendra Khichar Mahadev Meena Naveenraj Palanisamy Archana Gaur Mahendra K Garg 

机构地区：[1]Department of General Medicine,All India Institute of Medical Sciences-Bibinagar,Hyderabad 508126,Telangana,India [2]Department of General Medicine,All India Institute of Medical Sciences,Jodhpur 342005,Rajasthan,India [3]Department of Anaesthesiology and Critical Care,All India Institute of Medical Sciences,Jodhpur 342005,Rajasthan,India [4]Department of General Medicine,All India Institute of Medical Sciences,Bhopal 462020,Madhya Pradesh,India [5]Department of General Medicine,ESIC Medical College&Hospital,Chennai 600021,Tamilnadu,India [6]Department of Physiology,All India Institute of Medical Sciences-Bibinagar,Hyderabad 508126,Telangana,India [7]Department of Endocrinology&Metabolism,All India Institute of Medical Sciences,Jodhpur 342005,Rajasthan,India

出　　处：《World Journal of Critical Care Medicine》2024年第3期42-52,共11页世界重症医学杂志

基　　金：approved by All India Institute of Medical Sciences-Jodhpur Institutional Review Board(AIIMS/IEC/2020-21/2003).

摘　　要：BACKGROUND Patients with coronavirus disease 2019(COVID-19)infection frequently have hypertension as a co-morbidity,which is linked to adverse outcomes.Antihypertensives may affect the outcome of COVID-19 infection.AIM To assess the effects of antihypertensive agents on the outcomes of COVID-19 infection.METHODS A total of 260 patients were included,and their demographic data and clinical profile were documented.The patients were categorized into nonhypertensive,angiotensin-converting enzyme inhibitor/angiotensin receptor blocker(ACEI/ARB),calcium channel blocker(CCB),a combination of ACEI/ARB and CCB,and beta-blocker groups.Biochemical,hematological,and inflammatory markers were measured.The severity of infection,intensive care unit(ICU)intervention,and outcome were recorded.RESULTS The mean age of patients was approximately 60-years-old in all groups,except the nonhypertensive group.Men were predominant in all groups.Fever was the most common presenting symptom.Acute respiratory distress syndrome was the most common complication,and was mostly found in the CCB group.Critical cases,ICU intervention,and mortality were also higher in the CCB group.Multivariable logistic regression analysis revealed that age,duration of antihypertensive therapy,erythrocyte sedimentation rate,high-sensitivity C-reactive protein,and interleukin 6 were significantly associated with mortality.The duration of antihypertensive therapy exhibited a sensitivity of 70.8%and specificity of 55.7%,with a cut-off value of 4.5 years and an area under the curve of 0.670(0.574-0.767;95%confidence interval)for COVID-19 outcome.CONCLUSION The type of antihypertensive medication has no impact on the clinical sequence or mortality of patients with COVID-19 infection.However,the duration of antihypertensive therapy is associated with poor outcomes.

关 键 词：ANTIHYPERTENSIVE COVID-19 HYPERTENSION MORTALITY OUTCOME 

分 类 号：R563.1[医药卫生—呼吸系统]